Evidence map›Paper›PMID 39701287›Full record

ArticleTransplantation and cellular therapy2025

Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care Intervention.

Abigail G Cohen, Christina Cho, Emily Patterson, Jessica Magaldi, Tara Doga, Kristine Naputo, Kelsey Alvarez, Elizabeth Giles, Grace Yang, Afshana Hoque and 9 more

Abstract read
In one paragraph

Article in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Abigail G CohenAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: cohena2@mskcc.org.
Christina ChoAdult Stem Cell Transplantation and Cellular Therapy Program, Hackensack University Medical Center, Hackensack, New Jersey.
Emily PattersonDepartment of Nursing, Massachusetts General Hospital, Boston, Massachusetts.
Jessica MagaldiAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Tara DogaAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Kristine NaputoDepartment of Social Work, Memorial Sloan Kettering Cancer Center, New York, New York.
Kelsey AlvarezDepartment of Nursing, Mount Sinai Hospital, New York, New York.
Elizabeth GilesCarelon Health, New York, New York.
Grace YangAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Afshana HoqueDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Dana KramerSupportive Care Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Sean DevlinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
David NemirovskyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
William E RosaDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
Jessica I GoldbergSupportive Care Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Miguel-Angel PeralesAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Andrew S EpsteinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Judith E NelsonSupportive Care Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Heather LandauAdult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundHematopoietic stem cell transplant (HSCT) has curative potential but also relatively high morbidity and mortality. Patients have multidimensional palliative care (PC) needs throughout the transplant process. However, PC is not routinely offered to patients with hematologic malignancies. National guidelines recommend PC concurrent with curative hematologic disease treatment, including HSCT.

objectivesOur goal was to determine the feasibility and acceptability of incorporating early and ongoing discussions of patients' core health-related values (HRVs) for patients with hematologic malignancies undergoing HSCT. STUDY

designWe designed and implemented a pilot study evaluating the transplant team's use of a brief, structured guide with eight open-ended questions to support patients' articulation of their HRVs. All English-speaking patients undergoing HSCT from March 2021 to March 2022 in two outpatient HSCT clinics were eligible and offered enrollment. HRV discussions were planned pretransplant, and then at 5 time points post-transplant (Day 10-14, Day 30, Day 100, 6 months, 1 year). Clinicians and patients were surveyed to assess the feasibility and acceptability of this primary PC intervention.

results31 patients, mostly male (61%) and white (68%), with plasma cell (58%) and myeloid (42%) diseases participated in 149 values discussions. Initial discussions averaged 17.7 minutes; subsequent discussions were 13.3 minutes. Most patients were comfortable discussing their values and indicated it was important and helpful for them, as well as beneficial for their caregivers. Patients reported feeling heard and understood by their care team following values discussions. Clinicians were comfortable having the discussions, felt they were beneficial, and indicated learning new information about their patients beyond their diagnosis.

conclusionsIncorporating discussions of patients' HRVs into routine HSCT care was found to be feasible and acceptable in this pilot study. Feedback from patients and providers was overwhelmingly positive. Based on these results, the program has been refined and expanded to include all patients receiving HSCT and chimeric antigen receptor T cell (CAR-T) therapy, with plans to study the clinical impact of this approach.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationPalliative CareAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedPilot ProjectsSurveys and QuestionnairesTransplantation, AutologousTransplantation, HomologousPrimary palliative care, Health related valuesStem cell transplant

Identifiers

PMID39701287
PMCPMC11792765

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.